var data={"title":"Terbinafine (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Terbinafine (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/8195?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=terbinafine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Terbinafine (systemic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=terbinafine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Terbinafine (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566188\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>LamISIL;</li>\n      <li>Terbinex [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9480131\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Terbinafine;</li>\n      <li>Auro-Terbinafine;</li>\n      <li>CO Terbinafine;</li>\n      <li>Dom-Terbinafine;</li>\n      <li>GD-Terbinafine;</li>\n      <li>JAMP-Terbinafine;</li>\n      <li>Lamisil;</li>\n      <li>Mylan-Terbinafine;</li>\n      <li>PHL-Terbinafine;</li>\n      <li>PMS-Terbinafine;</li>\n      <li>Q-Terbinafine;</li>\n      <li>Riva-Terbinafine;</li>\n      <li>Sandoz-Terbinafine;</li>\n      <li>Teva-Terbinafine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566197\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Oral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567990\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Lamisil granules have been discontinued in the United States for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis:</b> Oral: Tablet: Fingernail: 250 mg once daily for 6 weeks; Toenail: 250 mg once daily for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed doses:</i> If a dose is missed, take as soon as remembered, unless it is less than 4 hours before the next dose is due.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea capitis (patients &gt;35 kg):</b> Oral: Granules: 250 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea corporis, tinea cruris (off-label use):</b> Oral: 250 mg daily in 1 to 2 divided doses for 2 to 6 weeks (Del Palacio Hernanz 1990, Gupta 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea pedis/manuum (off-label use):</b> Oral: 250 mg once daily for 2 weeks (Gupta 2008, Tausch 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sporotrichosis, lymphocutaneous and cutaneous (off-label use):</b> Oral: 500 mg twice daily as alternative therapy; treat for 2 to 4 weeks after resolution of all lesions (usual duration: 3 to 6 months) (Kauffman 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567989\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=terbinafine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Terbinafine (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Lamisil granules have been discontinued in the United States for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea capitis:</b> Oral: Granules: Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;25 kg: 125 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">25 to 35 kg: 187.5 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;35 kg: 250 mg once daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis (off-label use) (Gupta 1997):</b> Oral: Tablet: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 to 20 kg: 62.5 mg once daily for 6 weeks (fingernails) <b>or</b> 12 weeks (toenails)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">20 to 40 kg: 125 mg once daily for 6 weeks (fingernails) <b>or</b> 12 weeks (toenails)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;40 kg: 250 mg once daily for 6 weeks (fingernails) <b>or</b> 12 weeks (toenails)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567991\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution; refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567992\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, clearance is decreased 50% in patients with CrCl &le;50 mL/minute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567993\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Contraindicated in chronic or active hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247741\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terbinex: 250 mg &amp; 1% [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamISIL: 125 mg (1 ea [DSC], 14 ea [DSC]); 187.5 mg (1 ea [DSC], 14 ea [DSC]) [contains polyethylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamISIL: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566193\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24525299\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Terbinex Kit contains terbinafine 250 mg tablets and hydroxypropyl-chitosan 1% nail lacquer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50624329\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Lamisil granules have been discontinued in the United States for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49037895\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Lamisil: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524717.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//CovC0x0ey2BbNY46aAsKLBP/BsAitBmX3QpPKyuyT5w==&amp;TOPIC_ID=9922\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM524717.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9572845\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer tablets without regard to meals. Administer granules with food; sprinkle granules on a spoonful of pudding or other soft, nonacidic food (eg, mashed potatoes); swallow entire spoonful without chewing; do not mix granules with applesauce or other fruit-based foods.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247742\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onychomycosis (tablets only):</b> Treatment of onychomycosis of the toenail or fingernail caused by dermatophytes (tinea unguium).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tinea capitis (granules only):</b> Treatment of tinea capitis in patients 4 years and older.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470473\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Sporotrichosis (lymphocutaneous and cutaneous); Tinea corporis/tinea cruris; Tinea pedis/manuum</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9566184\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Terbinafine may be confused with terbutaline </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LamISIL may be confused with LaMICtal, Lomotil</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247732\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (6%; children: 2%), pruritus (1% to 3%), urticaria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (3% to 6%), vomiting (&lt;1%; children: 5%), dyspepsia (4%), upper abdominal pain (children: 4%), dysgeusia (3%; may be severe and result in weight loss, anxiety, and depression), nausea (2% to 3%), abdominal pain (children: 2%), pharyngolaryngeal pain (children: 2%), toothache (children: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Liver enzyme disorder (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Vision color changes (children: 5%; color confusion), decreased visual acuity (children: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (children: 10%), cough (children: 6%), upper respiratory tract infection (children: 5%), nasal congestion (children: 2%), rhinorrhea (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&lt;1%; children: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute generalized exanthematous pustulosis, ageusia, agranulocytosis, alopecia, altered sense of smell, anaphylaxis, anemia, angioedema, anosmia, anxiety, arthralgia, auditory impairment, bullous dermatitis, cholestasis, cutaneous lupus erythematosus, depression, DRESS syndrome, erythema multiforme, exacerbation of psoriasis, exacerbation of systemic lupus erythematosus, exfoliative dermatitis, fatigue, flu-like symptoms, hemolytic-uremic syndrome, hepatic insufficiency, hepatic failure, hepatitis, hypersensitivity reaction, hypoesthesia, increased creatine phosphokinase, lens disease, malaise, myalgia, pancreatitis, pancytopenia, paresthesia, psoriasiform eruption, retinopathy, rhabdomyolysis, serum sickness-like reaction, severe neutropenia, skin photosensitivity, Stevens-Johnson syndrome, systemic lupus erythematosus, thrombocytopenia, thrombotic thrombocytopenic purpura, tinnitus, toxic epidermal necrolysis, vasculitis, vertigo, visual field defect</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247745\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to terbinafine or any component of the formulation; chronic or active hepatic disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247730\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allylamine antifungal hypersensitivity: Use caution in patients sensitive to allylamine antifungals (eg, naftifine, butenafine); cross-sensitivity to terbinafine may exist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Has been reported with use; instruct patients to report depressive symptoms/mood changes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Taste disturbance (including loss of taste) may occur and severe cases resulting in decreased food intake, weight loss, anxiety or depression have been reported; resolution may be delayed (eg, several weeks to &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent. Discontinue therapy in patients with symptoms of taste disturbance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Transient decreases in absolute lymphocyte counts were observed in clinical trials; severe neutropenia (reversible upon discontinuation) has also been reported. Monitor CBC in patients with preexisting immunosuppression if therapy is to continue &gt;6 weeks. Discontinue therapy if ANC &le;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic failure: Cases of hepatic failure, some leading to liver transplant or death, have been reported. May occur in patients with and without preexisting hepatic disease; severity of hepatic events and/or outcomes may be worse in patients with active or chronic hepatic disease. Perform baseline and periodic liver function tests; discontinue use if clinical evidence of liver injury develops (eg, nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, pale stools) or elevated liver function tests occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious skin and hypersensitivity reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, drug reaction with eosinophilia and systemic symptoms [DRESS] syndrome) have occurred. If progressive skin rash or signs and symptoms of a hypersensitivity reaction occur, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Although rare, changes in the ocular lens and retina have been reported; discontinuation of therapy may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory effects: Smell disturbance (including loss of smell) has been reported; resolution may be delayed (eg, &gt;1 year) following discontinuation of therapy or in some cases, disturbance may be permanent. Discontinue therapy in patients with symptoms of smell disturbance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, have been reported (some fatal). Discontinue if TMA occurs; consider diagnosis of TMA with unexplained thrombocytopenia and anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease (Lupus): Precipitation or exacerbation of cutaneous or systemic lupus erythematosus has been observed; discontinue if signs and/or symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use is contraindicated in patients with active or chronic hepatic disease; clearance is reduced by ~50% in hepatic cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (CrCl &le;50 mL/minute); clearance is reduced by ~50%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Due to potential toxicity, confirmation of diagnostic testing of nail or skin specimens prior to treatment of onychomycosis or dermatomycosis is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567975\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247734\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9922&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amitriptyline: Terbinafine (Systemic) may increase the serum concentration of Amitriptyline.  Management: Monitor for increased effects/toxicity of amitriptyline during concomitant administration with terbinafine. Reduced dosages of amitriptyline may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desipramine: Terbinafine (Systemic) may increase the serum concentration of Desipramine.  Management: Monitor for increased effects/toxicity of desipramine during concomitant administration with terbinafine. Reduced dosages of desipramine may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipramine: Terbinafine (Systemic) may increase the serum concentration of Imipramine.  Management: Monitor for increased effects/toxicity of imipramine during concomitant administration with terbinafine. Reduced dosages of imipramine may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nortriptyline: Terbinafine (Systemic) may increase the serum concentration of Nortriptyline.  Management: Monitor for increased effects/toxicity of nortriptyline during concomitant administration with terbinafine. Reduced dosages of nortriptyline may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Terbinafine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247736\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247747\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Avoid use in pregnancy since treatment of onychomycosis is postponable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9567969\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Terbinafine is excreted in breast milk; the milk/plasma ratio is 7:1. Breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247739\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests at baseline and periodically during treatment; CBC (if used &gt;6 weeks; immunosuppressed patients only); taste and/or smell disturbances</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247728\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic allylamine derivative that inhibits squalene epoxidase, a key enzyme in sterol biosynthesis in fungi. This results in a deficiency in ergosterol within the fungal cell membrane and results in fungal cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247744\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Children and Adults: &gt;70% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributed to sebum and skin predominantly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Plasma: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic predominantly via CYP1A2, 3A4, 2C8, 2C9, and 2C19 to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Children 36% to 64%; Adults: 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal half-life: 200 to 400 hours; very slow release of drug from skin and adipose tissues occurs; effective half-life: Children: 27 to 31 hours; Adults: ~36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Children and Adults: Within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%, primarily as inactive metabolites); feces (20%) (Debruyne 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Children (14 to 68 kg): 15.6 to 26.7 L/hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9574689\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LamISIL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $978.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Terbinafine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $383.54</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amizil (PH);</li>\n      <li>Antifin (CN, PK);</li>\n      <li>Atifan (CZ, EE);</li>\n      <li>Camisan (MY);</li>\n      <li>Cutis (LK);</li>\n      <li>Deolate (NZ);</li>\n      <li>Derfin (BD);</li>\n      <li>Dermafin (MY);</li>\n      <li>Dermasil (IL);</li>\n      <li>Dermatin (DE);</li>\n      <li>Dermax (ZA);</li>\n      <li>Dicil (EC);</li>\n      <li>EU2000 (TH);</li>\n      <li>Finex (PY);</li>\n      <li>Fungasil (MT);</li>\n      <li>Funginix (DK);</li>\n      <li>Fungitech (TW);</li>\n      <li>Fungizid (DE);</li>\n      <li>Fungster (BE);</li>\n      <li>Funhotek (UA);</li>\n      <li>Funzal (CO);</li>\n      <li>Interbi (HK, ID);</li>\n      <li>L:isim (MY, SG);</li>\n      <li>Lamifen (AE, JO, PH, QA, SA);</li>\n      <li>Lamisil (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CY, CZ, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Lamisil AT (ID);</li>\n      <li>Lamisil Dermgel (FR, IL);</li>\n      <li>Lamisil Once (AE, AU, HK, KR, KW, LB, PH, QA, SA, TH, VN);</li>\n      <li>Lamisilate (FR);</li>\n      <li>Lamizyl (UA);</li>\n      <li>Lammifen (KW);</li>\n      <li>Lapiderm (KR);</li>\n      <li>Micoset (CL);</li>\n      <li>Micozone (EC);</li>\n      <li>Muzona (HK);</li>\n      <li>Mycelvan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nailderm (IE);</li>\n      <li>Patir (IL);</li>\n      <li>Periafin (TW);</li>\n      <li>Ronasil Derm Gel (KR);</li>\n      <li>Sebifin (IN);</li>\n      <li>Skinabin (BD);</li>\n      <li>SolvEasy Tinea Cream (AU);</li>\n      <li>Tamsil (AU);</li>\n      <li>Tenabin (KR);</li>\n      <li>Terbex (BD);</li>\n      <li>Terbifin (BD, HK);</li>\n      <li>Terbihexal (AU);</li>\n      <li>Terbix (CR, DO, GT, HN, NI, PA);</li>\n      <li>Terekol (AR);</li>\n      <li>Terfex (VE);</li>\n      <li>Terfine (TW);</li>\n      <li>Terfung (TW);</li>\n      <li>Tiersil Once (KR);</li>\n      <li>Zabel (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Rahman SM, Herron J, Fallon-Friedlander S, et al, &ldquo;Pharmacokinetics of Terbinafine in Young Children Treated for Tinea Capitis,&rdquo; <i>Pediatr Infect Dis J</i>, 2005, 24(10):886-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/16220086/pubmed\" target=\"_blank\" id=\"16220086\">16220086</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Backer M, De Vroey C, Lesaffre E, et al, &ldquo;Twelve Weeks of Continuous Oral Therapy for Toenail Onychomycosis Caused by Dermatophytes: A Double-Blind Comparative Trial of Terbinafine 250 mg/day Versus Itraconazole 200 mg/day,&rdquo; <i>J Am Acad Dermatol</i>, 1998, 38(5 Pt 3):S57-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/9594939/pubmed\" target=\"_blank\" id=\"9594939\">9594939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. <i>Clin Pharmacokinet</i>. 2001;40(6):441-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/11475469/pubmed\" target=\"_blank\" id=\"11475469\">11475469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2194715\"></a>Del Palacio Hernanz A, Lopez Gomez S, Gonzalez Lastra F, et al. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. <i>Clin Exp Dermatol.</i> 1990;15(3):210-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/2194715/pubmed\" target=\"_blank\" id=\"2194715\">2194715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedlander SF, Aly R, Krafchik B, et al, &ldquo;Terbinafine in the Treatment of <i>Trichophyton</i> Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study,&rdquo; <i>Pediatrics</i>, 2002, 109(4):602-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/11927703/pubmed\" target=\"_blank\" id=\"11927703\">11927703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. <i>Mycopathologia.</i> 2008;166(5-6):353-367. doi: 10.1007/s11046-008-9109-0. Epub 2008 May 14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/18478357/pubmed\" target=\"_blank\" id=\"18478357\">18478357</a>]</span><span class=\"doi\">10.1007/s11046-008-9109-0</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Sibbald RG, Knowles SR, et al, &ldquo;Terbinafine Therapy May Be Associated With the Development of Psoriasis De Novo or Its Exacerbation: Four Case Reports and a Review of Drug Induced Psoriasis,&rdquo; <i>J Am Acad Dermatol</i>, 1997, 36(5 Part 2):858-862.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/9146568/pubmed\" target=\"_blank\" id=\"9146568\">9146568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta AK, Sibbald RG, Lynde CW, et al, &ldquo;Onychomycosis in Children: Prevalence and Treatment Strategies,&rdquo; <i>J Am Acad Dermatol</i>, 1997, 36(3 Pt 1):395-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/9091470/pubmed\" target=\"_blank\" id=\"9091470\">9091470</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones TC, &ldquo;Overview of the Use of Terbinafine in Children,&rdquo; <i>Br J Dermatol</i>, 1995, 132(5):683-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/7772471/pubmed\" target=\"_blank\" id=\"7772471\">7772471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, et al, &quot;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(10):1255-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamisil tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamisil granules [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9542675\"></a>Tausch I, Decroix J, Gwiedzdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. <i>Int J Dermatol.</i> 1998;37(2):140-142.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/terbinafine-systemic-drug-information/abstract-text/9542675/pubmed\" target=\"_blank\" id=\"9542675\">9542675</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9922 Version 187.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9566188\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9480131\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9566197\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9567990\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9567989\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9567991\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F9567992\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F9567993\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F247741\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9566193\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F24525299\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50624329\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49037895\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F9572845\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F247742\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470473\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9566184\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F247732\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F247745\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F247730\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9567975\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F247734\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F247736\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F247747\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9567969\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F247739\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F247728\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F247744\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9574689\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9922|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=terbinafine-systemic-patient-drug-information\" class=\"drug drug_patient\">Terbinafine (systemic): Patient drug information</a></li><li><a href=\"topic.htm?path=terbinafine-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Terbinafine (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}